TFDA has granted the approval for the active cancer immunotherapy OBI-833 to proceed to a Phase II clinical trial

1.Date of occurrence of the event: 2022/02/23 2.New drug name or code: Active cancer immunotherapy, OBI-833 3.Indication: OBI-833 is a therapeutic cancer vaccine against Globo H, which is classified as an active cancer immunotherapy. Once injected into the human body, the Globo H-CRM197 conjugate can elicit anti-Globo H antibodies to treat cancers. Potential subjects will […]

This article is password protected.

To view the content, please enter your password in the field below